Veterinary Emergency Group Announces Its Third Round of Funding With $100 Million in Financing Co-Led by D1 Capital Partners and Fidelity Management & Research Company LLC and Supported by Durable Capital Partners LP
– VEG announced a $100m financing round co-led by D1 Capital Partners and Fidelity Management & Research Company, and supported by Durable Capital Partners.
– This third round of financing will bring total equity raised to an estimated $150m since inception and positions VEG to continue to invest in its people by providing the best support system and work culture within the veterinary field.
Owlstone Medical Raises $58M in Funding
– Owlstone Medical is a Cambridge UK-based global leader in Breath Biopsy® for applications in early disease detection and precision medicine.
– Company raised $58m in funding.
– The round was led by Horizons Ventures, which now takes a seat on Owlstone Medical’s Board, and is joined by other existing and high-profile new investors from Asia, the Middle East and the United States.
– The new investment will be used to accelerate the company’s commercialization of its Breath Biopsy tests.
Memic Innovative Surgery Raises $96 Million
– Meemic Innovative Surgery raised $96m in a Series D financing round.
– The round was led by Peregrine Ventures and Ceros with participation from OurCrowd and Accelmed.
– Funding will support commercialization of the Hominis® robotic-assisted surgical platform in the U.S. and potentially in other countries around the world as the company also plans to expand marketing and sales efforts outside the U.S.
– The financing will also support continued research and development efforts including expanding the company’s portfolio of products and manufacturing scaleup, as well as provide world-class customer support and training.
Entrada Therapeutics Closes $116M Series B Financing
– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.
AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs
– AnchorDx announced the completion of a $40m Series C financing round.
– The round was led by OrbiMed and WuXi Huiying Investment.
– The company plans to use the new funds to accelerate the registration and commercialization of its NGS-based products for single-cancer, multi-cancer, and pan-cancer screening and early detection. The company also plans to deploy its technology to other major disease areas.
Mainstay Medical Receives US$108M Equity Financing
– Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity financing of US$108m.
– The round was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.
– Key existing investors participating include Sofinnova Partners (Capital Fund), KCK Group and Fountain Healthcare Partners.
